DE102005053926B3 - Use of antibacterial agent from mixture of plant drugs, comprises Rumex acetosa L.-family, Rumicis herba, Verbena officinalis, Sambucus nigra, Primula veris and Gentiana lutea, e.g. to treat infection on topical skin and mucous membrane - Google Patents

Abstract

Use of an antibacterial agent (I) from a mixture of plant drugs, comprises Rumex acetosa L., Rumex acetosella L., Rumex obtusifolius L., Rumex patientia L. and Rumex crispus L., Verbena officinalis, Sambucus nigra, Primula veris and Gentiana lutea, for the treatment of infection on topical skin and mucous membrane in the form of a galenic formulation as e.g. spray, tamponade or sink solution for nose and ear. Use of an antibacterial agent (I) from a mixture of plant drugs or an ethanolic/aqueous extract, comprises Rumex acetosa L., Rumex acetosella L., Rumex obtusifolius L., Rumex patientia L. and Rumex crispus L. (Rumicis herba), Verbena officinalis, Sambucus nigra, Primula veris and Gentiana lutea, for the protection and/or treatment of infection on topical skin and mucous membrane in the form of a galenic formulation as spray, ointment, emulsion, powder, liquid or solid preparation for the inhalation, compression, sore- and gum wadding, tamponade, tonsil solution, throat solution or sink solution for nose and ear. ACTIVITY : Antimicrobial; Dermatological; Respiratory-Gen. MECHANISM OF ACTION : None given.

Description

The The present invention relates to the use of an antibacterial By means of a mixture of plant drugs or an ethanolic / aqueous Extract thereof, the mixture of Rumex acetosa L., Rumex acetosella L., Rumex obtusifolius L., Rumex patientia L. and Rumex crispus L., (hereinafter referred to collectively as "Rumicis herba"), Verbena officinalis Sambucus nigra, Primula veris and Gentiana lutea, according to the generic term of claim 1.

The above medicinal plants are as secretolytic agents in infections of the upper Respiratory system, especially in sinusitis, known.

Each individual drug contributes to the unique effectiveness of the composition:
Gentiana lutea (yellow gentian) usually uses the root medicinally. Among the ingredients are, inter alia, various Secoiridoidglykoside with expectorant effect.

From the aforementioned Rumex species, hereafter "Rumicis herba" (sorrel herb) called, are usually leaves and stems are used medicinally. This contains flavonoids, oxalic acid and various tannins as ingredients with anti-inflammatory Effect, which also the body's immune system positive support.

From Verbena officinalis (verbena) are preferably leaves and Stem medicinally used as the main ingredients iridoid glycosides, Phenylethanoidglykoside and flavonoids contain, whereby expectorant and antiviral effects are achieved.

From Sambucus nigra (Black Elderberry) typically become the flowers medicinal whose ingredients contain various flavonol glycosides and as the main active ingredient contains sambunigrin, a cyanogenic glycoside, which expectorant and antiviral by catching the flu virus spikes Cells and blocks their effects (Grabovac, A. and Ullmer, A., Austrian Apotheker-Verlagsgesellschaft m.b.H., 2003).

From Primula veris (cowslip) become flowers and goblet used medicinally. The ingredients include triterpene saponins and phenol glycosides, such as primulaverin. They have an expectorant effect and fight Viruses. The ingredients act as a mild secretolytic and expectorant in the treatment of respiratory diseases.

The combination of said medicinal plants is known as secretolytic agent under the registered trademark Sinupret ^® and on the market for about 70 years. The composition of the Sinupret ^® is preferably effective for inflammations and infections of the ear, nose and throat and is particularly suitable for the treatment of acute and chronic sinusitis.

Either Acute and chronic sinusitis are common. In three out of four make The sinusitis develops as a result of a cold with one Extension to the paranasal sinuses, which is accompanied by a mucosal inflammation.

The Respiratory tracts range from the main nasal cavity to the various sinuses to the alveoli. To the nasal sinuses counting the frontal sinuses, the ethmoidal cells, the sphenoid sinus and the maxillary sinuses. All called bone cavities are lined with mucous membrane inside and lead through narrow openings, the ostia, in the Nasal cavity.

The surface The respiratory system is protective Slime coated, on the soil particles and pathogens such as e.g. Viruses, bacteria or fungi that enter with the breath. The mucus contains Defensive substances that attack the invading substances and render them harmless. So that the foreign substances from the body can be flushed out, The mucus is usually with the help of the cilia of the Ciliated epithelium is transported towards the pharynx, where it is swallowed can be.

Around to ward off infection-related respiratory diseases the mucous membrane unhindered over Protective and cleaning mechanisms have. For the removal of the with pathogens laden mucus, the unimpeded function of the cilia is indispensable, which are wavy Movements transport the mucus as well as the functional and thin mucus.

at an infection and inflammatory processes The upper respiratory tract is the protective and cleaning mechanisms of the Mucosa only more limited functioning.

For example solve viruses such as rhinoviruses, adenoviruses or coronaviruses inflammatory reactions of the mucous membranes, causing the mucous membrane to swell up and produce increased mucus. there it comes first too watery, subsequently to viscous mucus flow. In the course of inflammation the nasal mucosa can the ostia of the sinuses Slurry and obstruct the flow of mucus or even prevent. this leads to to a jam in the sinuses, which with tough Mucus goes along, which then leads to a loss of function or Loss of function of the cilia leads and after all a loss of Cleansing mechanism of the mucosa causes. Such a microenvironment favored in particular the rapid multiplication of ubiquitous microorganisms.

at longer Duration of this unfavorable Conditions, such as a swollen mucous membrane and viscous mucus sticky cilia, It can lead to chronic sinusitis, with the result of a permanent damage the mucous membrane and the ciliated epithelium.

respiratory relevant Pathogens, which also understood in particular ENT-relevant germs For example, Staphylococcus can be found in the mucus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus mutans or Haemophilus influenzae.

In the prior art, it is for example from the DE 103 41 579 A1 Applicant is aware that extracts of Gentiana lutea have antibacterial activity against some of the above germs.

C. Ismail: Pharmacological effects of Sinupret ^® in HNO 2005 [Suppl.] 53: S38-S42 (published online on April 2, 2005) describes the antibacterial effect of orally administered Sinupret ^® in a mouse model.

outgoing From this prior art, it is therefore an object of the present invention Invention, other medical applications for the beginning described plant mixture and extracts thereof, to develop.

The solution This object is achieved by the characterizing features of the claim 1.

Under The above-mentioned pathogens can also be found against methicillin resistant Staphylococcus aureus strain, called MRSA. Against this Bacterium are standard antibiotics such as β-lactam antibiotics, for example Oxacillin, penicillin and amoxicillin, without effect, as with too often Use of antibiotics can develop resistance. An additional These germs carry risk to surgical intensive care units where she to pneumonia, Cause wound infections and sepsis can.

Especially The present invention relates to the topical application of a antibacterial agent from a mixture of plant drugs or an ethanolic / aqueous Extract thereof, the mixture of Rumex acetosa L., Rumex acetosella L., Rumex obtusifolius L., Rumex patientia L. and Rumex crispus L., (hereinafter and in the claims with the collective term "Rumicis herba "), Verbena officinalis Sambucus nigra, Primula veris and Gentiana lutea consists.

These plants are part of the vertriebeen under the well known trade name Sinupret ^® Sekretolytikums the assignee of the present application. Gentiana lutea was known to have an antibacterial effect. In the investigations of the Applicant, however, it has completely surprisingly been found that not only a combination of the plant species in the form of the raw drugs or an ethanolic / aqueous extract thereof also unfolds a strong non-additive antibacterial effect, but also taken each plant by itself.

The medicinal plants used in Sinupret ^® are specifically selected, examined and further processed. The resulting consistent quality of the drug is achieved through optimized breeding and harvesting strategies and strict quality control.

In the case of upper airway obstruction due to viscous mucus, the ingredients of the composition used (Gentiana lutea: Rumicis herba: Verbena officinalis: Sambucus nigra: Primula veris = 1: 3: 3: 3: 3) induce the formation of fresh, fluid slime, whereby the above-described process of mucus solution and the removal and reduction of inflammatory symptoms achieved Sinupret ^® gently re-establishes the self-cleansing power of the respiratory system and at the same time develops a strong antibacterial effect. A hallmark of Sinupret ^® is its high compatibility, because the dosage determined by the applicant rarely cause side effects in patients, and no drug interactions are known.

With The present invention is a plant mixture (or ethanolic / aqueous extracts thereof) with decongestant and expectorant, as well as additional provided strong antibacterial effects.

in the Mucus-living and multiplying microbes (viruses, bacteria, Fungi) are killed or inhibited in their multiplication, creating an existing or new the resulting infection process is contained or even prevented.

The antibacterial agent can thus be beneficial in the treatment used by infections caused by respiratory pathogens become. The expectorant and anti-inflammatory effect is through the additional antibacterial effect supplements. This causes an infection of the upper respiratory tract in addition to the release of the zähflüssigen- mite-laden mucus mitigated by killing and / or Reduction of the proliferation of bacterial pathogens contained or even completely brought to a standstill.

By the invention described above is e.g. Sinusitis diseased Patient in a gentle manner without synthetic chemical components treated. Drug is also characterized by a high degree of compatibility with regard to its Interactions with other drugs and in terms of rarely occurring side effects in compliance with the manufacturer predetermined dosage.

The Antibacterial composition is especially against respiratory relevant Pathogen effective, being especially against grampositive cocci like Staphylococcus aureus, Staphylococcus aureus (MRSA), Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae and Streptococcus mutans, against Gram-negative rod bacteria such as Haemophilus influenzae, as well as against Enterobacteriaceae faecalis antibacterial Effectiveness shows.

The antibacterial effectiveness is by MBK values and the LD90 and / or LD50 characterizes.

With MBK is called the minimum bactericidal concentration. among them is the lowest concentration of an active ingredient to understand under in vitro conditions for a defined inoculum of bacteria within a specified Exposure time kills more than 99.9% of the introduced microorganisms.

With LD50 and LD90, the lethal doses, are the lowest concentrations an active ingredient, which within a specified Exposure time more than 50 or 90% of the introduced microorganisms kill.

MTC values antibacterial compositions are in the range from approx. 0.2-50% Vol (Explanation for this see page 12), in particular about 0.2-30% Vol, preferably about 0.2-12% Vol and preferably about 0.2-3% Vol. To antibacterial Being effective, the LD90 covers a range of about 0.1-50% Vol, in particular about 0.1-20% Vol, preferably about 0.1-10% Vol and preferably about 0.1-3% vol. The LD50 moves accordingly in a range of about 0.1-50% Vol, in particular about 0.1-20% Vol, preferably about 0.1-10% vol and preferably about 0.1-3% vol.

The Antibacterial composition preferably contains an extract from Gentiana lutea, Rumicis herba, Verbena officinalis, Sambucus nigra and primula veris in a ratio of 1: 3: 3: 3: 3.

The antibacterial composition may be present as lyophilisate.

The galenic formulation of the antibacterial agent can be selected from sprays, especially nose, throat, or disinfectant sprays; Ointments, emulsions, powders, powders, liquid or solid preparations for inhalation, compresses, deposits, in particular wound and gum deposits, tamponades, including for teeth, rinsing solutions for nose and ear, in particular in combination with physiological and hyperosmolar concentrations of salts or salt mixtures , preferably saline, especially sea salt or Emser ^® salt.

Of course you can the formulation is pharmaceutically customary Excipients included.

Consequently The present invention relates to the use of the antibacterial Plant-based agent for the treatment of respiratory-related Pathogens triggered Infections and the production of a topically applied drug.

Further Advantages and features of the present invention are due to the description of embodiments as well as the drawing. It shows:

1 the MBK, LD90 and LD50 of the mixture Sinupret ^® PM 03-009 in the investigated agents;

2 the MBK, LD90 and LD50 Sinupret the mixture PM ^® 04-013 in the investigated agents;

3 the MBK, LD90 and LD50 of the Sinupret ^® drops PM 03-010 in the investigated pathogens;

4 the MBK, LD90 and LD50 of the Sinupret ^® PM -Tropfen 04-014 in the investigated agents;

5 the MBK, LD90 and LD50 of the Tinct. Primulae flos PM 03-007;

6 the MBK, LD90 and LD50 of the Tinct. Sambuci flos PM 03-006;

7 the MBK, LD90 and LD50 of the Tinct. Rumicis herba PM 03-005; and

8th the MBK, LD90 and LD50 of the Tinct. Verbena herba PM 03-004

Examples

I. Experimental part and proof of antibacterial activity in mixed extracts

For the purpose In the present study, the mixed extracts of Rumicis Herba, Verbena officinalis, Sambucus nigra, Primula veris and Gentiana lutea for the preparation of the antibacterial agent accordingly the declarations for Sinupret drops as well as in a variant prepared with a solvent modified in ethanol concentration.

• Rumex acetosa L.
• Synonym: Lapathum acetosa SCOP.
• Synonym: Lapathum pratense LAM.
• Synonym: Acetosa pratensis MILLER
• Rumex acetosella L.
• Synonym: Rumex infestus SALISB.
• Rumex obtusifolius L.
• Synonym Lapathum obtusifolium MOENCH
• Synonym Lapathum obtusantum MONTAD.
• Synonym Rumex actus WALLR.
• Synonym Rumex silvestris WALLR.
• Rumex patientia L.
• Synonym Rumex olympicus BOISS.
• Synonym Lapathum hortense MOENCH
• Rumex crispus L.
• Rumex thyrsiflorus FINGERH.
• Synonym Acetosa thyrsiflora FINGERH.
• Synonym Rumex acetosa subsp. auriculatus WALLR.

The collective term "Rumicis herba" means a mixture of the following species:

• Rumex acetosa L.
• Synonym: Lapathum acetosa SCOP.
• Synonym: Lapathum pratense LAM.
• Synonym: Acetosa pratensis MILLER
• Rumex acetosella L.
• Synonym: Rumex infestus SALISB.
• Rumex obtusifolius L.
• Synonym Lapathum obtusifolium MOENCH
• Synonym Lapathum obtusantum MONTAD.
• Synonym Rumex actus WALLR.
• Synonym Rumex silvestris WALLR.
• Rumex patientia L.
• Synonym Rumex olympicus BOISS.
• Synonym Lapathum hortense MOENCH
• Rumex crispus L.
• Rumex thyrsiflorus FINGERH.
• Synonym Acetosa thyrsiflora FINGERH.
• Synonym Rumex acetosa subsp. auriculatus WALLR.

The The above species are medically permitted.

The term "Sinupret ^® mixture" means the extraction of Gentiana lutea, Rumicis herba, Verbena officinalis, Sambucus nigra and Primula Veris Rohdrogenmischung than 50 vol .-% ethanol.

The term "Sinupret ^® -Tropfen" means as drops completely formulated ethanol solution of extracts of Gentiana lutea, Rumicis herba, Verbena officinalis, Sambucus nigra, and Primula veris in 19 vol .-% ethanol.

In the 1 to 4 are the results of the investigation of the pharmaceutical preparation "Sinupret ^® corresponding extract (drug / extract ratio 1:11) as it is present in" Sinupret ^® drops ", and to an analog extract with modified ethanol content in the extractant shown.

To simplify the presentation, the group Sinupret ^® -Tropfen and the other is called Sinupret ^® mixture.

3: 3: 3: under Sinupret ^® mixture to a composition comprising an ethanolic / aqueous extract of Gentiana lutea, Rumicis herba, Verbena officinalis, Sambucus nigra and Primula Veris 1 ratio is hereinafter also understood 3 includes.

The detection of the antibacterial effect of the present antibacterial agent was carried out using Sinupret ^® -Tropfen and Sinupret mixture to a bacterial strain Panel reference for relevant pathogens of the upper respiratory tract.

Furthermore were single extracts single plant drugs tested for their antibacterial effect. This turned out to be surprising found out that each of the individual drugs has an outstanding antibacterial Effect in the test panel showed. These results are following to the investigations shown in tabular form and with diagrams.

The The pathogens used are Gram positive cocci such as Staphylococcus aureus, Staphylococcus aureus MRSA, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus mutans and Gram-negative rod bacteria such as Haemophilus influenzae and Enterobacteriaceae faecalis.

The used strains are at the American Type Culture Collection (Rockville, Manland) commercially available with the following numbers: Staphylococcus aureus (ATCC 12600), Staphylococcus aureus MRSA (ATCC 33593), Staphylococcus epidermidis (ATCC 14990), Streptococcus pyogenes (ATCC 12344), Streptococcus pneumoniae (ATCC 33400), Streptococcus mutans (ATCC 35668), Haemophilus influenzae (ATCC 49247 and ATCC 33391) and Enterobacteriaceae faecalis (AER) (ATCC 51299).

The Target of the performed Investigation was the quantification of certain antibacterial properties herbal extracts across from a reference strain panel of potential pathogens of infections of the upper respiratory tract and multidrug-resistant pathogens.

The In vitro studies were performed in double-blind studies.

The test microbes were exposed to the investigational product in concentrations of 10 ⁴ -10 ⁵ / ml for 2 hours. Of the test microbes subcultured on hard soils, the minimum bactericidal concentration, as well as the LD90 and LD50, both in% vol of the test volume, were determined.

Carrying out the investigations

1. Preparation of the investigational medicinal products

Various herbal extracts, PM 03-009 / 10 and PM 04-013 / 14, have been used as lyophilisates to at least substantially free them from ethanol (see 1 to 4 ).

The Lyophilisate was under the responsibility of Prof. Dr. med. Maune and dr. shepherd at the University Otolaryngology Clinic Kiel produced on a laboratory scale by means of a cryo-lyophilizate plant of Christ. there for cell culture experiments an alcohol-free solution was mandatory (vitality of the cells studied); Consequently was a quick one Continuation of the experimental procedure ensured.

Explanation of the percentages Volume ("% Vol"):
A defined volume of the solution provided by the Applicant was lyophilized. The lyophilisate was then given the same volume, with only saline or cell culture solution added.

The Quantities are to be understood as follows: The reconstituted lyophilisate was in a concentration of x% of the reconstituted lyophilisate (= 100%) used to achieve the described effect; Consequently cause x% of the solution provided by the applicant the described effect.

The Lyophilisate was first with sterile dist. with a quantity of 1/10 of each Initial volume solved and subsequently diluted 1:10 in the assay. The highest Concentration therefore corresponds to 100% vol based on the initial volume. The dilution took place in two-fold dilution steps of 100% Vol, 50% Vol, ..., 0.0125% Vol. There were total 14 concentrations examined.

2. Preparation of the solid breeding grounds

Solid media and shake cultures were prepared from the following ingredients in a known manner. Sterile distilled water, 0.85% NaCl, sterile sodium phosphate buffer 10 mM, pH 7.0-7.4 (prepared from 1.78 g / l Na ₂ HPO ₄ .2H ₂ O and 1.38 g / l NaH ₂ PO ₄ * H ₂ O), Brain Heart Glucose Agar and Brain Heart Broth (BHI) (Difco), Columbia Agar + 5% Sheep Blood (Oxoid), Cook's Blood Agar, and Fildes Broth (Difco) used for the production of appropriate solid culture media for the cultivation of plate cultures and appropriate media for the cultivation of liquid cultures.

3. Production of precultures

In 10 ml of brain-heart-glucose broth, overnight cultures of the test strains were cultured. Subsequently, subcultures of 50 μl or 100 μl of the bacterial suspensions were incubated in 10 ml brain-heart-glucose-broth for 2.5 hours at 37 ° C. in shake or stand cultures (strain-dependent). An absorbance reading was made against BHI broth blanked in the photometer at 578 nm. Subsequently, the cultures were centrifuged at 2800 rpm for 15 minutes and the pellets resuspended in 10 ml of sodium phosphate buffer. An absorbance measurement was carried out against sodium phosphate buffer as a blank in the photometer at 578 nm. After preparation of appropriate calibration curves, the bacterial concentrations were each adjusted to 10 ⁴ -10 ⁵ / ml in sodium phosphate buffer. Germ count was performed on BHI plates in serial dilutions of 10 ^-1 -10 ^-3 in NaCl, the plated volume being 100 μl. The BHI plates were incubated for 21-22 hours at 37 ° C in the incubator.

The Incubation with extracts was carried out by loading a microtiter plate with 10 .mu.l test sample per well in concentration increments of 100-0.0125% vol. The concentration steps were analogous to the concentration steps the investigational medicinal products. The Microtiter plate was used for 2 hours at 37 ° C in the shaking incubator cultured. The control was a bacterial suspension of 100 .mu.l + 10 .mu.l Aqua dest.

The germ count was determined in accordance with DIN 58958-1 on BHI plates with NaCl dilution series of 10 ^-1 -10 ^-3 , with a plated volume of 100 ul. The BHI plates were incubated for 21-22 hours at 37 ° C in the incubator.

The evaluation of the antibacterial effectiveness of the compositions used was carried out in accordance with DIN 58940-1 by determining the MBK, LD90 and LD50. Their results are shown in Tables 1 to 4 and 1 to 4 specified.

Table 1: PM 03-009 Sinupret ^® mixture (Fig. 1)

Table 2: PM 04-013 Sinupret ^® mixture (Fig. 2)

Table 3: PM 03-010 Sinupret ^® -Tropfen (Fig. 3)

Table 4: PM 04-014 Sinupret ^® -Tropfen (Fig. 4)

at the determination of the above concentrations for MBK, LD90 and LD50 only those values were used that were below 100, because only these values for a gentle and medically appropriate application into consideration can be pulled.

at determining the concentration ranges of MBK, LD90 and LD50 The smallest and largest became medically appropriate concentrations indicated; the interval nesting of the concentration ranges results from the preferred concentration ranges within which one Application of the antibacterial mixture from a medical point of view makes sense.

The Effect of the antibacterial agent is of course also depending on the concentration of the bacteria.

There Escherichia coli (ATCC 11775) and Pseudomonas aeruginosa (ATCC 10145) as negative control were not affected by any of the extracts, The antibacterial effect of the agents seems generic or species specific to be.

II proof the antibacterial effect of the individual drugs

The following tinctures were used in an analogous manner as the investigated mixed preparations under Chapter I. for bioassay with the test strains (also as lyophilisate, as described under I.):
Product name: PM03-004
Tinct. Verbenae herba, about 44 vol .-% ethanol.
Product name: PM03-005
Tinct. Rumicis herba, about 47 vol .-% ethanol
Product name: PM03-006
Tinct. Sambuci flos, about 44% ethanol by volume
Product name: PM03-007
Tinct. Primulae flos, about 46 vol .-% ethanol.

The results of the antibacterial tests are shown in Tables 5 to 8 below and in the accompanying Tables 5 to 8th shown.

Table 5: Tinct. Primulae flos (Fig. 5)

Table 6: Tinct. Sambuci flos (Fig. 6)

Table 7: Tinct. Rumicis herba (Fig. 7)

Table 8: Tinct. Verbena herba (Fig. 8)

It thus showed a broad, pronounced antibacterial effect the agent both as a mixture and in the individual drug extracts. The The effect was particularly pronounced on ENT-relevant pathogens. especially opposite Streptococcus pneumoniae and Streptococcus pyogenes and Staphylococcus aureus. The antibacterial agent showed a pronounced efficacy across from the Staphylococcus aureus MRSA strain, which is difficult to combat is. Its infectious Spread - especially in hospitals - could so far only by strict compliance with hospital hygiene Activities, such as the isolation of infected patients or antibacterial Therapies of those affected, be prevented. These measures however, mean an extra Burden for the patients in both medical and psychological Respect.

With the use according to the invention Is it possible, especially in particularly affected places, such as hospitals, one Prevent the spread of this multidrug-resistant pathogen and thus to protect the patient from further painful infections Way, i. use without synthetic chemical components to have to, to protect.

by virtue of The ENT relevance of the tested pathogens means that it is also excellent everywhere suitable, where bacteria directly and directly local or topical fight can.

The Antibacterial agent can thus preferably - in addition to the systemic application - directly at the contaminated site, e.g. in the form of a biologically 100% degradable Disinfectant sprays or solution or Naturally also for direct topical application to skin and mucous membranes both be used on humans as well as on animals. There are different ones Forms of application. Particularly suitable are the formulations as a solution, Spray, creams, ointments and emulsions in the dermatological field human as well as veterinary medicine. Here, the antibacterial agent can be applied directly to the diseased skin area be applied and / or in the form of soaked compresses, deposits or tamponades are used.

Of particular interest is the use of the antibacterial agent throughout the entire course rich in diseases of the entire respiratory tract, especially the upper respiratory tract, here preferably in the area of the pharynx, nasal and paranasal sinus mucous membranes. Particular importance is attached to nasal rinsing, in particular in conjunction with salts, for example in combination with a physiological or hyperosmolar Emser ^salt® solution.

From Tonsillenpinsellösungen, gargles in pharyngeal infections to powder content preparations or nebuliser inhalation preparations extends the wide range of new applications.

Further Application and indication areas include wound and gum deposits, e.g. in the form of cotton liners or cotton thread liners which soaked with the antibacterial agent.

As well conceivable are ear irrigation with solutions, that contain the antibacterial agent in ear canal infections.

Claims (12)

Use of an antibacterial agent from a mixture of plant drugs or an ethanolic / aqueous extract thereof, wherein the mixture of Rumex acetosa L., Rumex acetosella L., Rumex obtusifolius L., Rumex patientia L. and Rumex crispus L., (Rumicis herba) , Verbena officinalis, Sambucus nigra, Primula veris and Gentiana lutea, characterized in that it is used for the protection and / or treatment of infections topically on skin and mucous membranes in the form of a galenic formulation as a spray, ointments, emulsions, powders, powders, Liquid or solid preparations for inhalation, compresses, wound and gum deposits, tamponades, Tonsillenpinsellösungen, gargle solutions or rinsing solutions for the nose and ear is applied. Use according to claim 1, characterized Gentiana lutea, Rumicis herba, Verbena officinalis, Sambucus nigra and primula veris in a ratio of 1: 3: 3: 3: 3 become. Use according to one of claims 1 or 2, characterized that the galenic formulation as a nose, throat spray or disinfectant spray is applied. Use according to one of claims 1 or 2, characterized that the tamponades also for Teeth applied become. Use according to one of claims 1 or 2, characterized that the rinsing solutions for nose and Ear in combination with physiological or hyperosmolar concentrations of salts or salt mixtures. Use according to one of claims 1 to 5, characterized that this antibacterial agents for the treatment of respiratory-related Pathogen causing diseases is used. Use according to claim 6, characterized that the Respiratory relevant pathogens are selected from gram positive Cocci, in particular Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus mutans and / or Gram-negative rod bacteria, especially Haemophilus influenzae. Use according to claim 7, characterized that the Pathogen an oxacillin / methicillin resistant Staphylococcus aureus strain is. Use according to claim 7, characterized that the Respiratory relevant pathogens are selected from Staphylococcus aureus (ATCC 12600), Staphylococcus aureus (MRSA) (ATCC 33593), Staphylococcus epidermidis (ATCC 14990), Streptococcus pneumoniae (ATCC 33400), Streptococcus pyogenes (ATCC 12344), Streptococcus mutans (ATCC 35668), Haemophilus influenzae (ATCC 49247 and ATCC 33391); as well as their mixtures. Use according to one of claims 1 to 6, characterized that the Pathogen Enterobacteriaceae faecalis (VRE), in particular Enterobacteriaceae faecalis (AER) (ATCC 51299). Use according to one of claims 1 to 10, characterized that this Antibacterial agent is used as a lyophilisate. Use according to one of claims 1 to 11, characterized that he for the galenic formulation of the antibacterial agent pharmaceutically conventional excipients starts.